Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 31;34(4):566-575.
doi: 10.1093/icvts/ivab291.

Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer-results from a retrospective analysis

Pieter J M Joosten  1 , Chris Dickhoff  2 , Vincent van der Noort  3 , Maarten Smeekens  4 , Rachel C Numan  1 , Houke M Klomp  1 , Judi N A van Diessen  5 , Jose S A Belderbos  5 , Egbert F Smit  6 , Kim Monkhorst  7 , Jan W A Oosterhuis  8 , Michel M van den Heuvel  6   9 , Max Dahele  10 , Koen J Hartemink  1
Affiliations

Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer-results from a retrospective analysis

Pieter J M Joosten et al. Interact Cardiovasc Thorac Surg. .

Abstract

Objectives: Chemoradiotherapy (CRT) has been the backbone of guideline-recommended treatment for Stage IIIA non-small cell lung cancer (NSCLC). However, in selected operable patients with a resectable tumour, good results have been achieved with trimodality treatment (TT). The objective of this bi-institutional analysis of outcomes in patients treated for Stage IIIA NSCLC was to identify particular factors supporting the role of surgery after CRT.

Methods: In a 2-centre retrospective cohort study, patients with Stage III NSCLC (seventh edition TNM) were identified and those patients with Stage IIIA who were treated with CRT or TT between January 2007 and December 2013 were selected. Patient characteristics as well as tumour parameters were evaluated in relation to outcome and whether or not these variables were predictive for the influence of treatment (TT or CRT) on outcome [overall survival (OS) or progression-free survival (PFS)]. Estimation of treatment effect on PFS and OS was performed using propensity-weighted cox regression analysis based on inverse probability weighting.

Results: From a database of 725 Stage III NSCLC patients, 257 Stage IIIA NSCLC patients, treated with curative intent, were analysed; 186 (72%) with cIIIA-N2 and 71 (28%) with cT3N1/cT4N0 disease. One hundred and ninety-six (76.3%) patients were treated by CRT alone (high-dose radiation with daily low-dose cisplatin) and 61 (23.7%) by TT. The unweighted data showed that TT resulted in better PFS and OS. After weighting for factors predictive of treatment assignment, patients with a large gross tumour volume (>120 cc) had better PFS when treated with TT, and patients with an adenocarcinoma treated with TT had better OS, regardless of tumour volume.

Conclusions: Patients with Stage IIIA NSCLC and large tumour volume, as well as patients with adenocarcinoma, who were selected for TT, had favourable outcome compared to patients receiving CRT. This information can be used to assist multidisciplinary team decision-making and for stratifying patients in studies comparing TT and definitive CRT.

Keywords: Chemoradiotherapy; Non-small cell lung cancer Stage IIIA; Surgery; Trimodality treatment; Tumour volume.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
(A–D) PFS and OS of patients with Stage IIIA NSCLC treated with CRT or TT. CRT: chemoradiotherapy; OS: overall survival; PFS: progression-free survival; TT: trimodality treatment.
Figure 2:
Figure 2:
PFS by treatment and nodal stage (N0-1 vs N2) after CRT or TT. CRT: chemoradiotherapy; PFS: progression-free survival; TT: trimodality treatment.
Figure 3:
Figure 3:
(A–C) PFS by treatment and GTV trichotomized into 3 categories, after CRT or TT. CRT: chemoradiotherapy; GTV: gross tumour volume; PFS: progression-free survival; TT: trimodality treatment.
Figure 4:
Figure 4:
(A–C) OS by treatment and GTV trichotomized into 3 categories, after CRT or TT. CRT: chemoradiotherapy; GTV: gross tumour volume; OS: overall survival; TT: trimodality treatment.
Figure 5:
Figure 5:
(A–D) PFS and OS by treatment and GTV, dichotomized into 2 categories (small GTV ≤ 120 cc and large GTV > 120 cc), after CRT or TT. CRT: chemoradiotherapy; GTV: gross tumour volume; OS: overall survival; PFS: progression-free survival; TT: trimodality treatment.
Figure 6:
Figure 6:
OS by treatment of patients with AC after CRT or TT. AC: adenocarcinoma; CRT: chemoradiotherapy; OS: overall survival; TT: trimodality treatment.
None
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Morgensztern MD, Ng SH, Gao F, Govindan R.. Trends in stage distribution for patients with non-small cell lung cancer: a national cancer database survey. J Thorac Oncol 2010;5:29–33. - PubMed
    1. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J. et al.; ESMO Guidelines Committee. Early-stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines. Ann Oncol 2017;28:iv1–21. - PubMed
    1. Bradley JD, Hu C, Komaki RR, Masters GA, Blumenschein GR, Schild SE. et al. Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non–small-cell lung cancer. J Clin Oncol 2020;38:706–14. - PMC - PubMed
    1. Eberhardt WE, Pöttgen C, Gauler TC, Friedel G, Veit S, Heinrich V. et al. Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE). J Clin Oncol 2015;33:4194–201. - PubMed
    1. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R. et al.; PACIFIC Investigators. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018;379:2342–50. - PubMed